Monday poster honored with special recognition awarded to top-rated abstracts
CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company's TransKingdom RNA interference (tkRNAi) technology will be the focus of three poster sessions featuring late-breaking research at the American Association for Cancer Research (AACR) meeting. The poster presentation scheduled for Monday afternoon, Safety and Efficacy of a tkRNAi Therapeutic Targeting Beta-Catenin (CTNNB1), received special recognition from the AACR Program Committee, which rated the abstract in the top three to four percent of those submitted. The AACR meeting will be held April 18 - 22, 2009, at the Colorado Convention Center in Denver, Colorado.
Sunday, April 19 Characterization of a Multiple Hairpin Expression Construct for TransKingdom RNA Interference (tkRNAi) 8 am - noon Hall B-F Cequent's Group Leader for Molecular Biology, Dr. Poster Section 27 AJ Wang will present data demonstrating that a single Poster board #10 tkRNAi construct can target multiple genes Abstract # LB-38 simultaneously and induce significant gene silencing. Data presented here targets oncogenes relevant for colon cancer, but this tkRNAi technology may also prove useful in treatments for other cancers, inflammatory diseases, and disorders Monday, April 20 Safety and Efficacy of a tkRNAi Therapeutic Targeting Beta-Catenin (CTNNB1) 1 - 5 pm Hall B-F Cequent's Director of Development, Alison Silva, will Poster Section 15 present novel data showing the safety and efficacy of Poster board #26 orally applied tkRNAi in non-human primates against Abstract #LB-123 beta-catenin. These findings open the door to clinical Highly Rated Phase I testing of Cequent's lead drug candidate Poster CEQ508, an orally administered tkRNAi therapeutic Presentation targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis). FAP is an inherited gastrointestinal disease that causes hundreds of polyps to form in the colon. Today, without prophylactic removal of the colon, people with FAP almost inevitably develop colon cancer, and there is no medical treatment available. Cequent's tkRNAi treatment might provide a safe and effective tool to prevent the formation of polyps and progression into cancer. Tuesday, April 21 Modulation of ABCB1-Mediated Multidrug Resistance (MDR) by TransKingdom RNA Interference (tkRNAi) 8 am - noon Hall B-F Resistance against chemotherapy frequently complicates Poster Section 26 the clinical treatment of patients with cancer. Poster board #6 Professor Herman Lage of Charite University Hospital, Abstract #LB-199 Berlin, Germany, will present data describing the targeting of chemotherapy resistance with tkRNAi. Here, Professor Lage demonstrates the effectiveness of using tkRNAi against an important multidrug resistance mechanism seen in solid cancers such as gastric carcinoma, ovarian cancer, and others.
About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/
|SOURCE Cequent Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved